Cancer IQ, Inc.

canceriq.com

CancerIQ helps providers use genetic information to predict, pre-empt, and prevent disease - starting with cancer. By making is easier to identify patients at risk, offer a genetic evaluation at point of care, and design a tailored cancer prevention plan - we can help healthcare systems get ahead of this costly and emotionally devastating disease.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

PACE® LIFE SCIENCES ACQUIRES BIOPHARMA GLOBAL, EXPANDING FDA REGULATORY AFFAIRS STRATEGY AND CONSULTING CAPABILITIES

Pace® Life Sciences | September 09, 2022

news image

Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization and a subsidiary of Pace®, a science and technology company, announced today that it has acquired Biopharma Global. Biopharma specializes in full-service regulatory support for orphan products to treat rare diseases and non-orphan products to treat indications with unmet medical needs. "Pace® provides great value in our marketplace through our technic...

Read More

EPIGENETIC CHANGES MAKE BREAST CANCER CELLS DRUG RESISTANT

LabRoots | January 20, 2020

news image

Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...

Read More

Pharma Tech

PHARMAJET PARTNER ZYDUS CADILA ANNOUNCES COVID-19 VACCINE EXPANSION PLAN TO MULTIPLE COUNTRIES WITH KOREAN FIRM

PharmaJet | January 05, 2022

news image

PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income...

Read More

Pharmacy Market

AIKIDO PHARMA ANNOUNCES STRATEGIC INTEREST IN ASP ISOTOPES INC.

AIkido Pharma Inc. | December 07, 2021

news image

AIkido Pharma Inc. announced that the Company secured a strategic equity interest in ASP Isotopes, Inc., which focuses on the non-nuclear supply of enriched isotopes. ASP Isotopes' Aerodynamic Separation Process is a method of enriching molybdenum-100 which is a stable isotope of molybdenum. Technetium-99m is the most used radioisotope in the nuclear imaging industry, but the supply chain, which involves the radioactive decay of molybdenum-99 has been fraught with problems dur...

Read More
news image

Pharma Tech

PACE® LIFE SCIENCES ACQUIRES BIOPHARMA GLOBAL, EXPANDING FDA REGULATORY AFFAIRS STRATEGY AND CONSULTING CAPABILITIES

Pace® Life Sciences | September 09, 2022

Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization and a subsidiary of Pace®, a science and technology company, announced today that it has acquired Biopharma Global. Biopharma specializes in full-service regulatory support for orphan products to treat rare diseases and non-orphan products to treat indications with unmet medical needs. "Pace® provides great value in our marketplace through our technic...

Read More
news image

EPIGENETIC CHANGES MAKE BREAST CANCER CELLS DRUG RESISTANT

LabRoots | January 20, 2020

Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...

Read More
news image

Pharma Tech

PHARMAJET PARTNER ZYDUS CADILA ANNOUNCES COVID-19 VACCINE EXPANSION PLAN TO MULTIPLE COUNTRIES WITH KOREAN FIRM

PharmaJet | January 05, 2022

PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income...

Read More
news image

Pharmacy Market

AIKIDO PHARMA ANNOUNCES STRATEGIC INTEREST IN ASP ISOTOPES INC.

AIkido Pharma Inc. | December 07, 2021

AIkido Pharma Inc. announced that the Company secured a strategic equity interest in ASP Isotopes, Inc., which focuses on the non-nuclear supply of enriched isotopes. ASP Isotopes' Aerodynamic Separation Process is a method of enriching molybdenum-100 which is a stable isotope of molybdenum. Technetium-99m is the most used radioisotope in the nuclear imaging industry, but the supply chain, which involves the radioactive decay of molybdenum-99 has been fraught with problems dur...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us